Literature DB >> 8200260

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

A Matsumoto1, E Tanaka, T Suzuki, H Ogata, K Kiyosawa.   

Abstract

Using conventional statistical analysis and multiple regression analysis, we investigated the viral and host factors that influence the response to recombinant interferon-alpha 2a therapy in patients with chronic hepatitis C. A total of 36 patients was randomly assigned to three administration schedules, 12 patients in each. Response to treatment was set as the criterion variable. Four variables were statistically significant in the conventional method in predicting a good therapeutic outcome: HCV genotype III and IV, lower histology activity index (HAI) score for liver, higher total dose of interferon administration, and lower serum HCV RNA concentration. In multiple regression analysis, a combination of the above four variables resulted in a higher multiple correlation coefficient (R = 0.84, P < 0.0001) using a stepwise method. Of those four, HCV genotype had the highest absolute value of standard partial regression coefficient (0.51). The HCV RNA concentration was correlated with HCV genotype and HAI score, whereas HCV genotype and HAI score showed no correlation. Thus, HCV RNA concentration was not statistically significant in multiple regression analysis. These findings indicate that HCV genotype, HAI score, and schedule of administration can be important predictors of the response to interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200260     DOI: 10.1007/bf02093793

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

Review 1.  The interferon system. A bird's eye view of its biochemistry.

Authors:  G C Sen; P Lengyel
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

2.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

3.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  The 5'-terminal sequence of the hepatitis C virus genome.

Authors:  H Okamoto; S Okada; Y Sugiyama; S Yotsumoto; T Tanaka; H Yoshizawa; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Jpn J Exp Med       Date:  1990-06

5.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

6.  Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in posttransfusion hepatitis patients during long-term follow-up.

Authors:  E Tanaka; K Kiyosawa; Y Nakatsuji; Y Inoue; T Miyamura; J Chiba; S Furuta
Journal:  J Med Virol       Date:  1993-04       Impact factor: 2.327

7.  Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up.

Authors:  M Yousuf; Y Nakano; E Tanaka; T Sodeyama; K Kiyosawa
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  Interferon-induced chronic active hepatitis?

Authors:  M O Silva; K R Reddy; L J Jeffers; M Hill; E R Schiff
Journal:  Gastroenterology       Date:  1991-09       Impact factor: 22.682

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  26 in total

1.  Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome.

Authors:  T Gayowski; N Singh; I R Marino; H Vargas; M Wagener; C Wannstedt; F Morelli; T Laskus; J J Fung; J Rakela; T E Starzl
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

2.  Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia.

Authors:  W T Hofgärtner; J A Kant; K E Weck
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C.

Authors:  Masayoshi Yada; Akihide Masumoto; Naoki Yamashita; Kenta Motomura; Toshimasa Koyanagi; Shigeru Sakamoto
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

Review 4.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 5.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

6.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Hepatocyte regeneration in chronic hepatitis C and interferon treatment: analysis of immunohistological identification of proliferating cell nuclear antigen (PCNA).

Authors:  M Hamada; T Kihira; K Takase; T Nakano; Y Tameda; Y Kosaka
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

8.  Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients.

Authors:  E Villa; P Buttafoco; A Merighi; A Grottola; I Ferretti; A Ferrari; F Callea; P Trande; A M Rebecchi; F Manenti
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

9.  Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.

Authors:  J Detmer; R Lagier; J Flynn; C Zayati; J Kolberg; M Collins; M Urdea; R Sánchez-Pescador
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China.

Authors:  Jin-Song Peng; Xu Wang; Man-Qing Liu; Dun-Jin Zhou; Jie Gong; Han-Ming Xu; Jian-Ping Chen; Hong-Hao Zhu; Wang Zhou; Wen-Zhe Ho
Journal:  Virus Res       Date:  2008-03-18       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.